Canagliflozin lowers PromarkerD DKD risk prediction scores
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- March 2023 Quarterly Activities Report and Appendix 4C
- Proteomics renews ISO 13485 and ISO 17025 accreditations
- New endometriosis test presented at international conference
- PromarkerD application for Australian MBS to be resubmitted
- Distribution agreement for PromarkerD in Britain extended
Later from Proteomics International Laboratories
- World Endometriosis Congress - New diagnostic test showcased
- Sonic Healthcare USA signs licence for PromarkerD in the US
- June 2023 Quarterly Activities Report and Appendix 4C
- OxiDx platform technology secures patent in Japan
- New oesophageal cancer test presented at global conference
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories